CytoDyn Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CYDY research report →
Companywww.cytodyn.com
CytoDyn Inc. operates as a clinical-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor in the areas of human immunodeficiency virus (HIV), non-alcoholic steatohepatitis (NASH), oncology, and such as coronavirus disease (COVID-19).
- CEO
- Jacob Lalezari
- IPO
- 2006
- Employees
- 9
- HQ
- Vancouver, WA, US
Price Chart
Valuation
- Market Cap
- $477.29M
- P/E
- -11.49
- P/S
- -80.68
- P/B
- -4.27
- EV/EBITDA
- -12.85
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.29%
- Op Margin
- 355.63%
- Net Margin
- 655.73%
- ROE
- 36.98%
- ROIC
- 104.25%
Growth & Income
- Revenue
- $-5,916,000 · 0.00%
- Net Income
- $3.75M · 107.51%
- EPS
- $0.00 · 103.59%
- Op Income
- $11.32M
- FCF YoY
- 20.19%
Performance & Tape
- 52W High
- $0.40
- 52W Low
- $0.21
- 50D MA
- $0.30
- 200D MA
- $0.28
- Beta
- 1.15
- Avg Volume
- 1.86M
Get TickerSpark's AI analysis on CYDY
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 20, 26 | Urbach Tanya Durkee | other | 574,385 |
| Mar 20, 26 | SIMES STEPHEN M | other | 574,385 |
| Mar 20, 26 | Ndhlovu Lishomwa C | other | 574,385 |
| Mar 20, 26 | Lalezari Jacob P | other | 4,874,691 |
| Mar 20, 26 | Hoffman Robert E. | other | 4,874,691 |
| Mar 20, 26 | Dunlap Ryan | other | 574,385 |
| Mar 20, 26 | Brunke Karen J | other | 574,385 |
| Mar 20, 26 | Blok Tyler | other | 3,249,794 |
| May 15, 25 | Hoffman Robert E. | other | 1,000,000 |
| May 15, 25 | Hoffman Robert E. | other | 0 |
Our CYDY Coverage
We haven't published any research on CYDY yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CYDY Report →